Why the study?
Does treating to lower systolic blood pressure targets improve clinical outcomes and balance safety in patients with cardiovascular disease?
Does treating to lower systolic blood pressure targets improve clinical outcomes and balance safety in patients with cardiovascular disease?
A systolic blood pressure target of <130 mmHg provides the optimal balance between reducing cardiovascular events and minimizing serious adverse effects in patients with cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Intensive SBP <120 mmHg reduces stroke/MI versus <160 mmHg but increases SAEs versus moderate targets; challenges very low targets and supports individualized goals in CVD.
Objective: The optimal blood pressure(BP) target has been a matter of debate. The recent SPRINT trial showed significant benefits of a BP target of <120 mmHg albeit with an increase in serious adverse effects (SAE). Design and method: PUBMED/EMBASE/CENTRAL were searched for randomized trials comparing treating to different BP targets. Trial arms were grouped into five systolic BP target categories: 1) <160 mmHg; 2) <150 mmHg; 3) <140 mmHg; 4) <130 mmHg and 5) <120 mmHg. Efficacy outcomes of stroke, myocardial infarction, death, cardiovascular death, heart failure and safety outcomes of SAE were evaluated using a network meta-analysis. Results: Seventeen trials that enrolled 55,163 patients with 204,103 patient-years of follow-up were included. There was a significant decrease in stroke (RR = 0.54; 95% CI 0.29–1.00) and myocardial infarction with systolic BP <120 mmHg (vs. <160 mmHg) (RR = 0.68; 95% CI 0.47–1.00). Sensitivity analysis using achieved systolic BP showed a 72%, 97% and 227% increase in stroke with systolic BP of <140 mmHg, <150 mmHg and <160 mm when compared with systolic BP <120 mmHg. There was no difference in death, cardiovascular death or heart failure when comparing any of the BP targets. However, the point estimate favored lower BP targets (<120 mmHg, <130 mmHg) when compared with higher BP targets (<140 mmHg or <150 mmHg). BP targets of <120 mmHg and <130 mmHg ranked #1 and #2 as the most efficacious target. There was a significant increase in SAE with systolic BP <120 mmHg vs. <150 mmHg (RR = 1.83; 95% CI 1.05–3.20) or vs. <140 mmHg (RR = 2.12; 95% CI 1.46–3.08). BP targets of <140 mmHg and <150 mmHg ranked #1 and #2 as the safest target for the outcome of SAE. Cluster plots for combined efficacy and safety showed that a systolic BP target of <130 mmHg had optimal balance between efficacy and safety. Conclusions: Among patients with cardiovascular disease, a systolic BP target of <130 mmHg achieved optimal balance between efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Bangalore et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: